Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.

Ciprotti M, Tebbutt NC, Lee FT, Lee ST, Gan HK, McKee DC, O'Keefe GJ, Gong SJ, Chong G, Hopkins W, Chappell B, Scott FE, Brechbiel MW, Tse AN, Jansen M, Matsumura M, Kotsuma M, Watanabe R, Venhaus R, Beckman RA, Greenberg J, Scott AM.

J Clin Oncol. 2015 Aug 20;33(24):2609-16. doi: 10.1200/JCO.2014.60.4256. Epub 2015 Jun 29.

2.

Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.

Nair JS, Ho AL, Tse AN, Coward J, Cheema H, Ambrosini G, Keen N, Schwartz GK.

Mol Biol Cell. 2009 Apr;20(8):2218-28. doi: 10.1091/mbc.E08-08-0885. Epub 2009 Feb 18.

3.

A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies.

Tse AN, Wu N, Patel D, Haviland D, Kemeny N.

Cancer Chemother Pharmacol. 2009 Oct;64(5):935-44. doi: 10.1007/s00280-009-0945-5. Epub 2009 Feb 17.

PMID:
19221752
4.

A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

Tse AN, Klimstra DS, Gonen M, Shah M, Sheikh T, Sikorski R, Carvajal R, Mui J, Tipian C, O'Reilly E, Chung K, Maki R, Lefkowitz R, Brown K, Manova-Todorova K, Wu N, Egorin MJ, Kelsen D, Schwartz GK.

Clin Cancer Res. 2008 Oct 15;14(20):6704-11. doi: 10.1158/1078-0432.CCR-08-1006.

5.

90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.

Tse AN, Sheikh TN, Alan H, Chou TC, Schwartz GK.

Mol Pharmacol. 2009 Jan;75(1):124-33. doi: 10.1124/mol.108.050807. Epub 2008 Sep 26.

6.

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.

Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM.

Mol Cancer Ther. 2008 Sep;7(9):2955-66. doi: 10.1158/1535-7163.MCT-08-0492.

7.

Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.

Fornier MN, Rathkopf D, Shah M, Patil S, O'Reilly E, Tse AN, Hudis C, Lefkowitz R, Kelsen DP, Schwartz GK.

Clin Cancer Res. 2007 Oct 1;13(19):5841-6.

8.

Targeting checkpoint kinase 1 in cancer therapeutics.

Tse AN, Carvajal R, Schwartz GK.

Clin Cancer Res. 2007 Apr 1;13(7):1955-60. Review.

9.

CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.

Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, Ma S, Moler EJ, Ni ZJ, Lopes de Menezes DE, Hibner B, Gesner TG, Schwartz GK.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):591-602.

Supplemental Content

Support Center